Business
Aquestive Therapeutics to Participate in Three Investor Conferences in September
WARREN, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and
About this update from Aquestive Therapeutics, Inc.
[{"type":"text","content":"WARREN, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that the management team will participate in three upcoming investor conferences in September as follows: H.C. Wainwright 23rd Annual Global Investment Conference: on demand corporate presentation available from September 13 - 15Lake Street Virtual Best Ideas Growth (BIG5) Conference: available for investor meetings on Tuesday, September 142021 Cantor Virtual Global Healthcare Conference: virtual corporate presentation on Thursday, September 30 at 8:00 a.m. ET A webcast of each presentation will be available on the “Events and Presentation” page of the Investors section of the Company’s website. A replay of each webcast will be available for 90 days following the events. For more information, please visit investors.aquestive.com. About Aquestive Therapeutics Aquestive Therapeutics is a pharmaceutical company that applies innovative technology to solve therapeutic problems and improve medicines for patients. The Company has commercialized one internally-developed proprietary product to date, Sympazan® (clobazam) oral film, has a commercial proprietary product pipeline focused on the treatment of diseases of the central nervous system, or CNS, and other unmet needs, and is developing orally administered complex molecules to provide alternatives to invasively administered standard of care therapies. The Company also collaborates with other pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm®, and has proven capabilities for drug development and commercialization. Forward-Looking StatementCertain statements in this press release include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,” “will,” or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the advancement of Libervant™ and other product candidates through the regulato...